Amyris Inc (AMRS) 0.46 $AMRS Amyris to Present
Post# of 273242
Posted On: 09/19/2016 5:01:12 AM
Amyris Inc (AMRS) 0.46 $AMRS
Amyris to Present at Singular Research 11th Annual "Best of The Uncovereds" Conference September 22, 2016
GlobeNewswire - Fri Sep 16, 7:30AM CDT
Amyris, Inc. (Nasdaq:AMRS), the industrial bioscience company, today announced that management will be presenting at the Singular Research "Best of The Uncovereds" Conference to be held September 22, 2016, at the Luxe Sunset Boulevard Hotel in Los Angeles.
AMRS: 0.46 (+0.02)
Amyris & Ginkgo Bioworks Complete Collaboration Agreement to Accelerate Commercialization of Bio-Based Products
GlobeNewswire - Thu Sep 15, 7:30AM CDT
Amyris, Inc. (Nasdaq:AMRS), the industrial bioscience company, today announced that it has completed a subsequent collaboration agreement with Ginkgo Bioworks, which is expected to be approved by the boards of both companies. The agreement finalizes details of how the two companies will jointly develop cultured products more efficiently and cost effectively, accelerating time to market. This breakthrough biotech collaboration was initially announced on June 29, 2016 and, upon board approval, both companies plan to move quickly to establish a leading position within the market for sustainable, bio-based products.
AMRS: 0.46 (+0.02)
Is Amyris (AMRS) Stock a Solid Choice Right Now?
Zacks Equity Research - Zacks Investment Research - Mon Sep 12, 7:41AM CDT
One stock that might be an intriguing choice for investors right now is Amyris, Inc. (AMRS)
AMRS: 0.46 (+0.02)
Amyris in Partnership with Boticario Group Named Gold Winner by Cosmetics Design for Breakthrough Ingredient - Neossance(R) Hemisqualane
GlobeNewswire - Fri Sep 09, 7:30AM CDT
Amyris, Inc. (Nasdaq:AMRS), the industrial bioscience company, is pleased to announce it has been named a Gold Winner for its Neossance(R) Hemisqualane high-performance ingredient by Cosmetics Design USA for 'Best Ingredient Made From Recycled Materials'. Cosmetics Design is partnering with the inaugural In-Cosmetics North America event to showcase this prestigious award for best ingredient developed using recycled, repurposed, by-products, or waste materials. In-Cosmetics shows are the biggest cosmetic ingredient trade shows in the B2B cosmetics industry that, this year, are convened in Paris, Seoul, New York, Sao Paulo, and Bangkok. Amyris submitted Neossance Hemisqualane for consideration of this award in partnership with its customer, Boticario Group, one of the largest cosmetics companies in Brazil with more than 4,000 stores. Boticario Group, which has demonstrated several benefits of using Amyris's innovative Neossance Hemisqualane ingredient in makeup remover applications it plans to launch, initiated the proposed entry for this award. The awards ceremony took place during the In-Cosmetics trade show on September 7th, 2016, in New York.
AMRS: 0.46 (+0.02)
Amyris to Present at Rodman & Renshaw 18th Annual Global Investment Conference on September 12, 2016
GlobeNewswire - Wed Sep 07, 7:30AM CDT
Amyris, Inc. (Nasdaq:AMRS), the industrial bioscience company, today announced that management will be presenting at the Rodman & Renshaw 18 Annual Global Investment Conference to be held September 11-13, 2016, at the Lotte New York Palace Hotel in New York City.
AMRS: 0.46 (+0.02)
Specialty Chemicals Stocks Technical Reports -- LyondellBasell Industries, Olin, Axalta Coating Systems, and Amyris
PR Newswire - Fri Aug 26, 6:35AM CDT
Stock-Callers.com today looks at four Specialty Chemicals equities, namely: LyondellBasell Industries N.V. (NYSE: LYB), Olin Corp. (NYSE: OLN), Axalta Coating Systems Ltd (NYSE: AXTA), and Amyris Inc. (NASDAQ: AMRS). The American Chemistry Council's global chemical production regional index ended the second quarter on a soft note, with the headline index rising only 0.1% on a three-month moving average basis in June. Download the free research reports on these stocks today:
AMRS: 0.46 (+0.02), LYB: 77.12 (+0.60), OLN: 18.64 (-0.38), AXTA: 27.35 (+0.02)
Biossance(TM) Launches The Detoxifier - A Breakthrough, Innovative Modeling Mask
GlobeNewswire - Wed Aug 24, 7:30AM CDT
Biossance(TM), the pioneer of sustainable beauty through biotechnology from Amyris, Inc. (Nasdaq:AMRS), today launched The Detoxifier, an innovative, new modeling mask for the face. This mask gently detoxifies and deeply hydrates the face, while calming and soothing the skin with squalane.
AMRS: 0.46 (+0.02)
Enviva Partners, LP (EVA) Catches Eye: Stock Rises 5.3%
Zacks Equity Research - Zacks Investment Research - Tue Aug 09, 7:30AM CDT
Enviva Partners, LP (EVA) shares rose over 5% in the last trading session.
EVA: 27.00 (+0.20), AMRS: 0.46 (+0.02)
Amyris Wins Three-Year, Multi-Million-Dollar Contract from U.S. Department of Energy to Further Manufacturing of Cellulose-Derived Farnesene
GlobeNewswire - Mon Aug 08, 7:30AM CDT
Amyris, Inc. (Nasdaq:AMRS), the industrial bioscience company, today announced that it has won a three-year multi-million dollar contract from the U.S. Department of Energy ('DOE') to further the manufacturing of cellulose-derived farnesene for biofuels. Amyris, in cooperation with Renmatix and Total New Energies USA ('Total'), will work to develop a manufacturing-ready process utilizing wood as the cellulosic feedstock to produce farnesene, a hydrocarbon building block used to manufacture a variety of products ranging from cosmetics to detergents, as well as base oils, lubricants, diesel and jet fuel.
AMRS: 0.46 (+0.02)
Amyris Reports Second Quarter 2016 Results
GlobeNewswire - Thu Aug 04, 3:00PM CDT
-- Q2 2016 GAAP revenues of $9.6 million (non-GAAP revenues of $12.4 million), led by product sales growth of 47% over Q2 2015 without any fuel sales
AMRS: 0.46 (+0.02)
Biofuel Stocks Earnings to Watch on Aug 4: REGI, AMRS, AMTX
Zacks Equity Research - Zacks Investment Research - Wed Aug 03, 8:05AM CDT
Few biofuel stocks that are scheduled to report second-quarter earnings on Aug 4.
REGI: 8.07 (-0.09), AMRS: 0.46 (+0.02), AMTX: 1.29 (-0.01), TOT: 45.78 (-1.07)
Amyris Enters Partnership with Biogen to Develop Alternative Cell Lines Supporting Production of Therapeutics
GlobeNewswire - Wed Aug 03, 7:30AM CDT
Amyris, Inc. (Nasdaq:AMRS), the industrial bioscience company, is pleased to announce it has entered into a funded partnership with Biogen, Inc. (Nasdaq:BIIB). The collaboration will explore the use of Amyris's advanced microbe engineering technology to evaluate and develop multiple host microorganisms as alternatives to mammalian cell lines for the production of therapeutic recombinant proteins.
BIIB: 304.51 (+1.69), AMRS: 0.46 (+0.02)
Amyris Fuels First Delivery of New Airbus A350-900 Airplane for Cathay Pacific as Part of Two-Year Biojet Agreement
GlobeNewswire - Mon Jun 13, 7:30AM CDT
Amyris, Inc. (Nasdaq:AMRS), the industrial bioscience company, today announced that, on May 29, 2016, Cathay Pacific commenced a two-year program of flights from Toulouse to Hong Kong using Amyris renewable jet fuel. The initial 12-hour flight was the longest flight using a renewable jet fuel to date, further underpinning the 'drop-in' characteristics of Amyris Biojet fuels. Cathay took delivery of a new Airbus A350-900 that flew from the Airbus facility in Toulouse, France, to Hong Kong using a 10% biofuel jet blend provided by Amyris with the commercial and industrial support of Total S.A. The combination of the new airplane's improvements in fuel efficiency (about 25% better than current aircraft) and the fuel's properties resulted in an estimated 30% reduction in CO2 emissions according to Cathay when compared to comparable flights in recent-generation aircraft using fossil fuels. All of Cathay's upcoming A350-900 aircraft deliveries over the next two years will use the Amyris/Total Biojet fuel.
AMRS: 0.46 (+0.02)
Amyris Announces Collaboration with Johnson & Johnson Innovation for Biosynthetic Drug Discovery
GlobeNewswire - Mon Jun 06, 7:30AM CDT
Amyris's uPharm Platform to be Used for Rapid Integrated Discovery and Production of Therapeutic Compounds
AMRS: 0.46 (+0.02)
Gen9 and Amyris Announce Supply Agreement for Synthetic DNA
BusinessWire - Thu Jun 02, 8:00AM CDT
Gen9 and Amyris today announced an agreement for the supply of multiple megabases of synthetic DNA content. The DNA is being supplied for use in Amyris, Inc.'s (Nasdaq: AMRS) microbial engineering pipeline for the development of products that improve performance and enable sustainable growth for some of the world's leading brands. The collaboration is part of Gen9's MAP program, fueled by the BioFab(R) DNA synthesis technology, which provides valuable, high-quality synthetic DNA constructs for industrial-scale use.
AMRS: 0.46 (+0.02)
Amyris to Participate in June 2016 Investor Conferences
GlobeNewswire - Fri May 27, 7:30AM CDT
Amyris, Inc. (Nasdaq:AMRS), the industrial bioscience company, today announced that it plans to participate in the following upcoming investor conferences in June 2016 and provide an update on new partnerships and growth opportunities as part of its business plan for the year.
AMRS: 0.46 (+0.02)
Amyris & CJ CheilJedang Corporation Creating Manufacturing and Sales Partnership
GlobeNewswire - Fri May 20, 7:30AM CDT
Amyris, Inc. (Nasdaq:AMRS), the industrial bioscience company, and South Korea-based CJ CheilJedang Corporation ("CJ"
(KRX:097950), today announced that the companies have signed a Memorandum of Understanding (MOU) to support large-scale manufacturing of Amyris's farnesene in existing CJ facilities. The arrangement described in the MOU would enable Amyris to utilize CJ's state of the art manufacturing capacity while minimizing the capital investment necessary to support projected near- and mid-term demand for product applications using farnesene. The partnership is also expected to include the opportunity for CJ Bio (division of CJ CheilJedang) to market select Amyris products in Asian markets as well as the potential for Amyris to develop several products for CJ Bio. The companies are targeting completing a definitive agreement by the first week of August 2016.
AMRS: 0.46 (+0.02)
Amyris to Participate in Upcoming Investor Conferences in May 2016
GlobeNewswire - Wed May 11, 1:42PM CDT
Amyris, Inc. (Nasdaq:AMRS), the industrial bioscience company, today announced that it plans to participate in the following upcoming investor conferences in May 2016.
AMRS: 0.46 (+0.02)
Amyris reports 1Q loss
Automated Insights - Tue May 10, 6:32PM CDT
EMERYVILLE, Calif. (AP) _ Amyris Inc. (AMRS) on Tuesday reported a loss of $15.3 million in its first quarter.
AMRS: 0.46 (+0.02)
Amyris First Quarter 2016 Results Deliver Strong Renewable Product Sales Growth and Continued Reduction in Operating Expenses
GlobeNewswire - Tue May 10, 4:09PM CDT
-- Q1 2016 revenues of $8.8 million, including product sales growth of 50% over Q1 2015
AMRS: 0.46 (+0.02)
Amyris to Present at Singular Research 11th Annual "Best of The Uncovereds" Conference September 22, 2016
GlobeNewswire - Fri Sep 16, 7:30AM CDT
Amyris, Inc. (Nasdaq:AMRS), the industrial bioscience company, today announced that management will be presenting at the Singular Research "Best of The Uncovereds" Conference to be held September 22, 2016, at the Luxe Sunset Boulevard Hotel in Los Angeles.
AMRS: 0.46 (+0.02)
Amyris & Ginkgo Bioworks Complete Collaboration Agreement to Accelerate Commercialization of Bio-Based Products
GlobeNewswire - Thu Sep 15, 7:30AM CDT
Amyris, Inc. (Nasdaq:AMRS), the industrial bioscience company, today announced that it has completed a subsequent collaboration agreement with Ginkgo Bioworks, which is expected to be approved by the boards of both companies. The agreement finalizes details of how the two companies will jointly develop cultured products more efficiently and cost effectively, accelerating time to market. This breakthrough biotech collaboration was initially announced on June 29, 2016 and, upon board approval, both companies plan to move quickly to establish a leading position within the market for sustainable, bio-based products.
AMRS: 0.46 (+0.02)
Is Amyris (AMRS) Stock a Solid Choice Right Now?
Zacks Equity Research - Zacks Investment Research - Mon Sep 12, 7:41AM CDT
One stock that might be an intriguing choice for investors right now is Amyris, Inc. (AMRS)
AMRS: 0.46 (+0.02)
Amyris in Partnership with Boticario Group Named Gold Winner by Cosmetics Design for Breakthrough Ingredient - Neossance(R) Hemisqualane
GlobeNewswire - Fri Sep 09, 7:30AM CDT
Amyris, Inc. (Nasdaq:AMRS), the industrial bioscience company, is pleased to announce it has been named a Gold Winner for its Neossance(R) Hemisqualane high-performance ingredient by Cosmetics Design USA for 'Best Ingredient Made From Recycled Materials'. Cosmetics Design is partnering with the inaugural In-Cosmetics North America event to showcase this prestigious award for best ingredient developed using recycled, repurposed, by-products, or waste materials. In-Cosmetics shows are the biggest cosmetic ingredient trade shows in the B2B cosmetics industry that, this year, are convened in Paris, Seoul, New York, Sao Paulo, and Bangkok. Amyris submitted Neossance Hemisqualane for consideration of this award in partnership with its customer, Boticario Group, one of the largest cosmetics companies in Brazil with more than 4,000 stores. Boticario Group, which has demonstrated several benefits of using Amyris's innovative Neossance Hemisqualane ingredient in makeup remover applications it plans to launch, initiated the proposed entry for this award. The awards ceremony took place during the In-Cosmetics trade show on September 7th, 2016, in New York.
AMRS: 0.46 (+0.02)
Amyris to Present at Rodman & Renshaw 18th Annual Global Investment Conference on September 12, 2016
GlobeNewswire - Wed Sep 07, 7:30AM CDT
Amyris, Inc. (Nasdaq:AMRS), the industrial bioscience company, today announced that management will be presenting at the Rodman & Renshaw 18 Annual Global Investment Conference to be held September 11-13, 2016, at the Lotte New York Palace Hotel in New York City.
AMRS: 0.46 (+0.02)
Specialty Chemicals Stocks Technical Reports -- LyondellBasell Industries, Olin, Axalta Coating Systems, and Amyris
PR Newswire - Fri Aug 26, 6:35AM CDT
Stock-Callers.com today looks at four Specialty Chemicals equities, namely: LyondellBasell Industries N.V. (NYSE: LYB), Olin Corp. (NYSE: OLN), Axalta Coating Systems Ltd (NYSE: AXTA), and Amyris Inc. (NASDAQ: AMRS). The American Chemistry Council's global chemical production regional index ended the second quarter on a soft note, with the headline index rising only 0.1% on a three-month moving average basis in June. Download the free research reports on these stocks today:
AMRS: 0.46 (+0.02), LYB: 77.12 (+0.60), OLN: 18.64 (-0.38), AXTA: 27.35 (+0.02)
Biossance(TM) Launches The Detoxifier - A Breakthrough, Innovative Modeling Mask
GlobeNewswire - Wed Aug 24, 7:30AM CDT
Biossance(TM), the pioneer of sustainable beauty through biotechnology from Amyris, Inc. (Nasdaq:AMRS), today launched The Detoxifier, an innovative, new modeling mask for the face. This mask gently detoxifies and deeply hydrates the face, while calming and soothing the skin with squalane.
AMRS: 0.46 (+0.02)
Enviva Partners, LP (EVA) Catches Eye: Stock Rises 5.3%
Zacks Equity Research - Zacks Investment Research - Tue Aug 09, 7:30AM CDT
Enviva Partners, LP (EVA) shares rose over 5% in the last trading session.
EVA: 27.00 (+0.20), AMRS: 0.46 (+0.02)
Amyris Wins Three-Year, Multi-Million-Dollar Contract from U.S. Department of Energy to Further Manufacturing of Cellulose-Derived Farnesene
GlobeNewswire - Mon Aug 08, 7:30AM CDT
Amyris, Inc. (Nasdaq:AMRS), the industrial bioscience company, today announced that it has won a three-year multi-million dollar contract from the U.S. Department of Energy ('DOE') to further the manufacturing of cellulose-derived farnesene for biofuels. Amyris, in cooperation with Renmatix and Total New Energies USA ('Total'), will work to develop a manufacturing-ready process utilizing wood as the cellulosic feedstock to produce farnesene, a hydrocarbon building block used to manufacture a variety of products ranging from cosmetics to detergents, as well as base oils, lubricants, diesel and jet fuel.
AMRS: 0.46 (+0.02)
Amyris Reports Second Quarter 2016 Results
GlobeNewswire - Thu Aug 04, 3:00PM CDT
-- Q2 2016 GAAP revenues of $9.6 million (non-GAAP revenues of $12.4 million), led by product sales growth of 47% over Q2 2015 without any fuel sales
AMRS: 0.46 (+0.02)
Biofuel Stocks Earnings to Watch on Aug 4: REGI, AMRS, AMTX
Zacks Equity Research - Zacks Investment Research - Wed Aug 03, 8:05AM CDT
Few biofuel stocks that are scheduled to report second-quarter earnings on Aug 4.
REGI: 8.07 (-0.09), AMRS: 0.46 (+0.02), AMTX: 1.29 (-0.01), TOT: 45.78 (-1.07)
Amyris Enters Partnership with Biogen to Develop Alternative Cell Lines Supporting Production of Therapeutics
GlobeNewswire - Wed Aug 03, 7:30AM CDT
Amyris, Inc. (Nasdaq:AMRS), the industrial bioscience company, is pleased to announce it has entered into a funded partnership with Biogen, Inc. (Nasdaq:BIIB). The collaboration will explore the use of Amyris's advanced microbe engineering technology to evaluate and develop multiple host microorganisms as alternatives to mammalian cell lines for the production of therapeutic recombinant proteins.
BIIB: 304.51 (+1.69), AMRS: 0.46 (+0.02)
Amyris Fuels First Delivery of New Airbus A350-900 Airplane for Cathay Pacific as Part of Two-Year Biojet Agreement
GlobeNewswire - Mon Jun 13, 7:30AM CDT
Amyris, Inc. (Nasdaq:AMRS), the industrial bioscience company, today announced that, on May 29, 2016, Cathay Pacific commenced a two-year program of flights from Toulouse to Hong Kong using Amyris renewable jet fuel. The initial 12-hour flight was the longest flight using a renewable jet fuel to date, further underpinning the 'drop-in' characteristics of Amyris Biojet fuels. Cathay took delivery of a new Airbus A350-900 that flew from the Airbus facility in Toulouse, France, to Hong Kong using a 10% biofuel jet blend provided by Amyris with the commercial and industrial support of Total S.A. The combination of the new airplane's improvements in fuel efficiency (about 25% better than current aircraft) and the fuel's properties resulted in an estimated 30% reduction in CO2 emissions according to Cathay when compared to comparable flights in recent-generation aircraft using fossil fuels. All of Cathay's upcoming A350-900 aircraft deliveries over the next two years will use the Amyris/Total Biojet fuel.
AMRS: 0.46 (+0.02)
Amyris Announces Collaboration with Johnson & Johnson Innovation for Biosynthetic Drug Discovery
GlobeNewswire - Mon Jun 06, 7:30AM CDT
Amyris's uPharm Platform to be Used for Rapid Integrated Discovery and Production of Therapeutic Compounds
AMRS: 0.46 (+0.02)
Gen9 and Amyris Announce Supply Agreement for Synthetic DNA
BusinessWire - Thu Jun 02, 8:00AM CDT
Gen9 and Amyris today announced an agreement for the supply of multiple megabases of synthetic DNA content. The DNA is being supplied for use in Amyris, Inc.'s (Nasdaq: AMRS) microbial engineering pipeline for the development of products that improve performance and enable sustainable growth for some of the world's leading brands. The collaboration is part of Gen9's MAP program, fueled by the BioFab(R) DNA synthesis technology, which provides valuable, high-quality synthetic DNA constructs for industrial-scale use.
AMRS: 0.46 (+0.02)
Amyris to Participate in June 2016 Investor Conferences
GlobeNewswire - Fri May 27, 7:30AM CDT
Amyris, Inc. (Nasdaq:AMRS), the industrial bioscience company, today announced that it plans to participate in the following upcoming investor conferences in June 2016 and provide an update on new partnerships and growth opportunities as part of its business plan for the year.
AMRS: 0.46 (+0.02)
Amyris & CJ CheilJedang Corporation Creating Manufacturing and Sales Partnership
GlobeNewswire - Fri May 20, 7:30AM CDT
Amyris, Inc. (Nasdaq:AMRS), the industrial bioscience company, and South Korea-based CJ CheilJedang Corporation ("CJ"
(KRX:097950), today announced that the companies have signed a Memorandum of Understanding (MOU) to support large-scale manufacturing of Amyris's farnesene in existing CJ facilities. The arrangement described in the MOU would enable Amyris to utilize CJ's state of the art manufacturing capacity while minimizing the capital investment necessary to support projected near- and mid-term demand for product applications using farnesene. The partnership is also expected to include the opportunity for CJ Bio (division of CJ CheilJedang) to market select Amyris products in Asian markets as well as the potential for Amyris to develop several products for CJ Bio. The companies are targeting completing a definitive agreement by the first week of August 2016. AMRS: 0.46 (+0.02)
Amyris to Participate in Upcoming Investor Conferences in May 2016
GlobeNewswire - Wed May 11, 1:42PM CDT
Amyris, Inc. (Nasdaq:AMRS), the industrial bioscience company, today announced that it plans to participate in the following upcoming investor conferences in May 2016.
AMRS: 0.46 (+0.02)
Amyris reports 1Q loss
Automated Insights - Tue May 10, 6:32PM CDT
EMERYVILLE, Calif. (AP) _ Amyris Inc. (AMRS) on Tuesday reported a loss of $15.3 million in its first quarter.
AMRS: 0.46 (+0.02)
Amyris First Quarter 2016 Results Deliver Strong Renewable Product Sales Growth and Continued Reduction in Operating Expenses
GlobeNewswire - Tue May 10, 4:09PM CDT
-- Q1 2016 revenues of $8.8 million, including product sales growth of 50% over Q1 2015
AMRS: 0.46 (+0.02)
(0)
(0)Scroll down for more posts ▼